Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

anti-GPC-1 ADC

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Adcendo

Drug class:

GPC-1-targeted antibody-drug conjugate

‹

›

GPC1 overexpression	Ovarian Cancer	GPC1 overexpression	Ovarian Cancer	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D
GPC1 overexpression	Brain Cancer	GPC1 overexpression	Brain Cancer	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D
GPC1 overexpression	Prostate Cancer	GPC1 overexpression	Prostate Cancer	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D
GPC1 overexpression	Bladder Cancer	GPC1 overexpression	Bladder Cancer	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D
GPC1 expression	Esophageal Squamous Cell Carcinoma	GPC1 expression	Esophageal Squamous Cell Carcinoma	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D
GPC1 overexpression	Cholangiocarcinoma	GPC1 overexpression	Cholangiocarcinoma	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D
GPC1 overexpression	Pancreatic Cancer	GPC1 overexpression	Pancreatic Cancer	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D	anti-GPC-1 ADC Sensitive: D – Preclinical anti-GPC-1 ADC Sensitive : D